FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance

The spread of multidrug-resistant (MDR) tuberculosis (TB) and extensively drug-resistant (XDR) TB hampers global efforts in the fight against tuberculosis. To enhance the development and evaluation of diagnostic tests quickly and efficiently, well-characterized strains and samples from drug-resistan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical microbiology 2017-04, Vol.55 (4), p.1066-1073
Hauptverfasser: Tessema, Belay, Nabeta, Pamela, Valli, Eloise, Albertini, Audrey, Collantes, Jimena, Lan, Nguyen Huu, Romancenco, Elena, Tukavdze, Nestani, Denkinger, Claudia M, Dolinger, David L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1073
container_issue 4
container_start_page 1066
container_title Journal of clinical microbiology
container_volume 55
creator Tessema, Belay
Nabeta, Pamela
Valli, Eloise
Albertini, Audrey
Collantes, Jimena
Lan, Nguyen Huu
Romancenco, Elena
Tukavdze, Nestani
Denkinger, Claudia M
Dolinger, David L
description The spread of multidrug-resistant (MDR) tuberculosis (TB) and extensively drug-resistant (XDR) TB hampers global efforts in the fight against tuberculosis. To enhance the development and evaluation of diagnostic tests quickly and efficiently, well-characterized strains and samples from drug-resistant tuberculosis patients are necessary. In this project, the Foundation for Innovative New Diagnostics (FIND) has focused on the collection, characterization, and storage of such well-characterized reference materials and making them available to researchers and developers. The collection is being conducted at multiple centers in Southeast Asia, South America, Eastern Europe, and soon the sub-Saharan Africa regions. Strains are characterized for their phenotypic resistances and MICs to first-line drugs (FLDs) and second-line drugs (SLDs) using the automated MGIT 960 system following validated procedures and WHO criteria. Analysis of resistance-associated mutations is done by whole-genome sequencing (WGS) using the Illumina NextSeq system. Mycobacterial interspersed repetitive-unit-variable-number tandem-repeat analysis and WGS are used to determine strain lineages. All strains are maintained frozen at -80°C ± 10°C as distinct mother and daughter lots. All strains are extensively quality assured. The data presented here represent an analysis of the initial part of the collection. Currently, the bank contains 118 unique strains with extracted genomic DNA and matched sputum, serum, and plasma samples and will be expanded to a minimum of 1,000 unique strains over the next 3 years. Analysis of the current strains by phenotypic resistance testing shows 102 (86.4%), 10 (8.5%), and 6 (5.1%) MDR, XDR, and mono/poly resistant strains, respectively. Two of the strains are resistant to all 11 drugs that were phenotypically tested. WGS mutation analysis revealed FLD resistance-associated mutations in the , , , , , and genes; SLD resistance in the , , , , and genes; and ethionamide resistance in the genes. Most important lineages are represented in the bank, and further collections have been initiated to increase geographic and lineage diversity. The bank provides highly characterized and high-quality strains as a resource for researchers and developers in support of the development and evaluation of new diagnostics and drug resistance detection tools.
doi_str_mv 10.1128/JCM.01662-16
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5377833</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1861575359</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-3e0102690b31ab486919e21e84cf350ab266e4a8ea3a3ea9af6bb5d92254dc693</originalsourceid><addsrcrecordid>eNqNkcFu1DAQhi0Eokvhxhn5yIEUTxw7MQck2FIoakEqi-BmTbyTbWjWXuykUl-Fp8WhpSo3TtZoPn3jmZ-xpyAOAMrm5cfl6YEArcsC9D22AGGaQmvx_T5bCGFUASDrPfYopR9CQFUp9ZDtlQ0IoUW5YL-Ojj8d8tXUUnTTEFKf-JcxYu_5W_QXrzjyM0phio54F-JcEEZ3TjFx9Gt-SJc0hN1cfgvxovcbHjxfURoTX4XcHsmN_PTKhRbdSLGftny8O2yWnNGAI2VZnDbzhD6N6B09Zg86HBI9uXn32dejd6vlh-Lk8_vj5ZuTwlVQj4UkAaLURrQSsK0abcBQCdRUrpNKYFtqTRU2hBIlocFOt61am7JU1dppI_fZ62vvbmq3tHbk8wEGu4v9FuOVDdjbfzu-P7ebcGmVrOtGyix4fiOI4eeUd7fbPjkaBvQUpmShMbVspDLiP1ANqlaZzeiLa9TFkFKk7vZHIOycvM3J2z_JW9AZf3Z3i1v4b9TyN1Plq-s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1861575359</pqid></control><display><type>article</type><title>FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance</title><source>American Society for Microbiology</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Tessema, Belay ; Nabeta, Pamela ; Valli, Eloise ; Albertini, Audrey ; Collantes, Jimena ; Lan, Nguyen Huu ; Romancenco, Elena ; Tukavdze, Nestani ; Denkinger, Claudia M ; Dolinger, David L</creator><contributor>Land, Geoffrey A.</contributor><creatorcontrib>Tessema, Belay ; Nabeta, Pamela ; Valli, Eloise ; Albertini, Audrey ; Collantes, Jimena ; Lan, Nguyen Huu ; Romancenco, Elena ; Tukavdze, Nestani ; Denkinger, Claudia M ; Dolinger, David L ; Land, Geoffrey A.</creatorcontrib><description>The spread of multidrug-resistant (MDR) tuberculosis (TB) and extensively drug-resistant (XDR) TB hampers global efforts in the fight against tuberculosis. To enhance the development and evaluation of diagnostic tests quickly and efficiently, well-characterized strains and samples from drug-resistant tuberculosis patients are necessary. In this project, the Foundation for Innovative New Diagnostics (FIND) has focused on the collection, characterization, and storage of such well-characterized reference materials and making them available to researchers and developers. The collection is being conducted at multiple centers in Southeast Asia, South America, Eastern Europe, and soon the sub-Saharan Africa regions. Strains are characterized for their phenotypic resistances and MICs to first-line drugs (FLDs) and second-line drugs (SLDs) using the automated MGIT 960 system following validated procedures and WHO criteria. Analysis of resistance-associated mutations is done by whole-genome sequencing (WGS) using the Illumina NextSeq system. Mycobacterial interspersed repetitive-unit-variable-number tandem-repeat analysis and WGS are used to determine strain lineages. All strains are maintained frozen at -80°C ± 10°C as distinct mother and daughter lots. All strains are extensively quality assured. The data presented here represent an analysis of the initial part of the collection. Currently, the bank contains 118 unique strains with extracted genomic DNA and matched sputum, serum, and plasma samples and will be expanded to a minimum of 1,000 unique strains over the next 3 years. Analysis of the current strains by phenotypic resistance testing shows 102 (86.4%), 10 (8.5%), and 6 (5.1%) MDR, XDR, and mono/poly resistant strains, respectively. Two of the strains are resistant to all 11 drugs that were phenotypically tested. WGS mutation analysis revealed FLD resistance-associated mutations in the , , , , , and genes; SLD resistance in the , , , , and genes; and ethionamide resistance in the genes. Most important lineages are represented in the bank, and further collections have been initiated to increase geographic and lineage diversity. The bank provides highly characterized and high-quality strains as a resource for researchers and developers in support of the development and evaluation of new diagnostics and drug resistance detection tools.</description><identifier>ISSN: 0095-1137</identifier><identifier>EISSN: 1098-660X</identifier><identifier>DOI: 10.1128/JCM.01662-16</identifier><identifier>PMID: 28100602</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Biological Specimen Banks ; Drug Resistance, Bacterial ; Humans ; International Cooperation ; Mycobacteriology and Aerobic Actinomycetes ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - isolation &amp; purification ; Tuberculosis, Multidrug-Resistant - diagnosis ; Tuberculosis, Multidrug-Resistant - microbiology</subject><ispartof>Journal of clinical microbiology, 2017-04, Vol.55 (4), p.1066-1073</ispartof><rights>Copyright © 2017 Tessema et al.</rights><rights>Copyright © 2017 Tessema et al. 2017 Tessema et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-3e0102690b31ab486919e21e84cf350ab266e4a8ea3a3ea9af6bb5d92254dc693</citedby><cites>FETCH-LOGICAL-c417t-3e0102690b31ab486919e21e84cf350ab266e4a8ea3a3ea9af6bb5d92254dc693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377833/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377833/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,3189,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28100602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Land, Geoffrey A.</contributor><creatorcontrib>Tessema, Belay</creatorcontrib><creatorcontrib>Nabeta, Pamela</creatorcontrib><creatorcontrib>Valli, Eloise</creatorcontrib><creatorcontrib>Albertini, Audrey</creatorcontrib><creatorcontrib>Collantes, Jimena</creatorcontrib><creatorcontrib>Lan, Nguyen Huu</creatorcontrib><creatorcontrib>Romancenco, Elena</creatorcontrib><creatorcontrib>Tukavdze, Nestani</creatorcontrib><creatorcontrib>Denkinger, Claudia M</creatorcontrib><creatorcontrib>Dolinger, David L</creatorcontrib><title>FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance</title><title>Journal of clinical microbiology</title><addtitle>J Clin Microbiol</addtitle><description>The spread of multidrug-resistant (MDR) tuberculosis (TB) and extensively drug-resistant (XDR) TB hampers global efforts in the fight against tuberculosis. To enhance the development and evaluation of diagnostic tests quickly and efficiently, well-characterized strains and samples from drug-resistant tuberculosis patients are necessary. In this project, the Foundation for Innovative New Diagnostics (FIND) has focused on the collection, characterization, and storage of such well-characterized reference materials and making them available to researchers and developers. The collection is being conducted at multiple centers in Southeast Asia, South America, Eastern Europe, and soon the sub-Saharan Africa regions. Strains are characterized for their phenotypic resistances and MICs to first-line drugs (FLDs) and second-line drugs (SLDs) using the automated MGIT 960 system following validated procedures and WHO criteria. Analysis of resistance-associated mutations is done by whole-genome sequencing (WGS) using the Illumina NextSeq system. Mycobacterial interspersed repetitive-unit-variable-number tandem-repeat analysis and WGS are used to determine strain lineages. All strains are maintained frozen at -80°C ± 10°C as distinct mother and daughter lots. All strains are extensively quality assured. The data presented here represent an analysis of the initial part of the collection. Currently, the bank contains 118 unique strains with extracted genomic DNA and matched sputum, serum, and plasma samples and will be expanded to a minimum of 1,000 unique strains over the next 3 years. Analysis of the current strains by phenotypic resistance testing shows 102 (86.4%), 10 (8.5%), and 6 (5.1%) MDR, XDR, and mono/poly resistant strains, respectively. Two of the strains are resistant to all 11 drugs that were phenotypically tested. WGS mutation analysis revealed FLD resistance-associated mutations in the , , , , , and genes; SLD resistance in the , , , , and genes; and ethionamide resistance in the genes. Most important lineages are represented in the bank, and further collections have been initiated to increase geographic and lineage diversity. The bank provides highly characterized and high-quality strains as a resource for researchers and developers in support of the development and evaluation of new diagnostics and drug resistance detection tools.</description><subject>Biological Specimen Banks</subject><subject>Drug Resistance, Bacterial</subject><subject>Humans</subject><subject>International Cooperation</subject><subject>Mycobacteriology and Aerobic Actinomycetes</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - isolation &amp; purification</subject><subject>Tuberculosis, Multidrug-Resistant - diagnosis</subject><subject>Tuberculosis, Multidrug-Resistant - microbiology</subject><issn>0095-1137</issn><issn>1098-660X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcFu1DAQhi0Eokvhxhn5yIEUTxw7MQck2FIoakEqi-BmTbyTbWjWXuykUl-Fp8WhpSo3TtZoPn3jmZ-xpyAOAMrm5cfl6YEArcsC9D22AGGaQmvx_T5bCGFUASDrPfYopR9CQFUp9ZDtlQ0IoUW5YL-Ojj8d8tXUUnTTEFKf-JcxYu_5W_QXrzjyM0phio54F-JcEEZ3TjFx9Gt-SJc0hN1cfgvxovcbHjxfURoTX4XcHsmN_PTKhRbdSLGftny8O2yWnNGAI2VZnDbzhD6N6B09Zg86HBI9uXn32dejd6vlh-Lk8_vj5ZuTwlVQj4UkAaLURrQSsK0abcBQCdRUrpNKYFtqTRU2hBIlocFOt61am7JU1dppI_fZ62vvbmq3tHbk8wEGu4v9FuOVDdjbfzu-P7ebcGmVrOtGyix4fiOI4eeUd7fbPjkaBvQUpmShMbVspDLiP1ANqlaZzeiLa9TFkFKk7vZHIOycvM3J2z_JW9AZf3Z3i1v4b9TyN1Plq-s</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Tessema, Belay</creator><creator>Nabeta, Pamela</creator><creator>Valli, Eloise</creator><creator>Albertini, Audrey</creator><creator>Collantes, Jimena</creator><creator>Lan, Nguyen Huu</creator><creator>Romancenco, Elena</creator><creator>Tukavdze, Nestani</creator><creator>Denkinger, Claudia M</creator><creator>Dolinger, David L</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>20170401</creationdate><title>FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance</title><author>Tessema, Belay ; Nabeta, Pamela ; Valli, Eloise ; Albertini, Audrey ; Collantes, Jimena ; Lan, Nguyen Huu ; Romancenco, Elena ; Tukavdze, Nestani ; Denkinger, Claudia M ; Dolinger, David L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-3e0102690b31ab486919e21e84cf350ab266e4a8ea3a3ea9af6bb5d92254dc693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Biological Specimen Banks</topic><topic>Drug Resistance, Bacterial</topic><topic>Humans</topic><topic>International Cooperation</topic><topic>Mycobacteriology and Aerobic Actinomycetes</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - isolation &amp; purification</topic><topic>Tuberculosis, Multidrug-Resistant - diagnosis</topic><topic>Tuberculosis, Multidrug-Resistant - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tessema, Belay</creatorcontrib><creatorcontrib>Nabeta, Pamela</creatorcontrib><creatorcontrib>Valli, Eloise</creatorcontrib><creatorcontrib>Albertini, Audrey</creatorcontrib><creatorcontrib>Collantes, Jimena</creatorcontrib><creatorcontrib>Lan, Nguyen Huu</creatorcontrib><creatorcontrib>Romancenco, Elena</creatorcontrib><creatorcontrib>Tukavdze, Nestani</creatorcontrib><creatorcontrib>Denkinger, Claudia M</creatorcontrib><creatorcontrib>Dolinger, David L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tessema, Belay</au><au>Nabeta, Pamela</au><au>Valli, Eloise</au><au>Albertini, Audrey</au><au>Collantes, Jimena</au><au>Lan, Nguyen Huu</au><au>Romancenco, Elena</au><au>Tukavdze, Nestani</au><au>Denkinger, Claudia M</au><au>Dolinger, David L</au><au>Land, Geoffrey A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance</atitle><jtitle>Journal of clinical microbiology</jtitle><addtitle>J Clin Microbiol</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>55</volume><issue>4</issue><spage>1066</spage><epage>1073</epage><pages>1066-1073</pages><issn>0095-1137</issn><eissn>1098-660X</eissn><abstract>The spread of multidrug-resistant (MDR) tuberculosis (TB) and extensively drug-resistant (XDR) TB hampers global efforts in the fight against tuberculosis. To enhance the development and evaluation of diagnostic tests quickly and efficiently, well-characterized strains and samples from drug-resistant tuberculosis patients are necessary. In this project, the Foundation for Innovative New Diagnostics (FIND) has focused on the collection, characterization, and storage of such well-characterized reference materials and making them available to researchers and developers. The collection is being conducted at multiple centers in Southeast Asia, South America, Eastern Europe, and soon the sub-Saharan Africa regions. Strains are characterized for their phenotypic resistances and MICs to first-line drugs (FLDs) and second-line drugs (SLDs) using the automated MGIT 960 system following validated procedures and WHO criteria. Analysis of resistance-associated mutations is done by whole-genome sequencing (WGS) using the Illumina NextSeq system. Mycobacterial interspersed repetitive-unit-variable-number tandem-repeat analysis and WGS are used to determine strain lineages. All strains are maintained frozen at -80°C ± 10°C as distinct mother and daughter lots. All strains are extensively quality assured. The data presented here represent an analysis of the initial part of the collection. Currently, the bank contains 118 unique strains with extracted genomic DNA and matched sputum, serum, and plasma samples and will be expanded to a minimum of 1,000 unique strains over the next 3 years. Analysis of the current strains by phenotypic resistance testing shows 102 (86.4%), 10 (8.5%), and 6 (5.1%) MDR, XDR, and mono/poly resistant strains, respectively. Two of the strains are resistant to all 11 drugs that were phenotypically tested. WGS mutation analysis revealed FLD resistance-associated mutations in the , , , , , and genes; SLD resistance in the , , , , and genes; and ethionamide resistance in the genes. Most important lineages are represented in the bank, and further collections have been initiated to increase geographic and lineage diversity. The bank provides highly characterized and high-quality strains as a resource for researchers and developers in support of the development and evaluation of new diagnostics and drug resistance detection tools.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>28100602</pmid><doi>10.1128/JCM.01662-16</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0095-1137
ispartof Journal of clinical microbiology, 2017-04, Vol.55 (4), p.1066-1073
issn 0095-1137
1098-660X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5377833
source American Society for Microbiology; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Biological Specimen Banks
Drug Resistance, Bacterial
Humans
International Cooperation
Mycobacteriology and Aerobic Actinomycetes
Mycobacterium tuberculosis
Mycobacterium tuberculosis - drug effects
Mycobacterium tuberculosis - isolation & purification
Tuberculosis, Multidrug-Resistant - diagnosis
Tuberculosis, Multidrug-Resistant - microbiology
title FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T13%3A40%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FIND%20Tuberculosis%20Strain%20Bank:%20a%20Resource%20for%20Researchers%20and%20Developers%20Working%20on%20Tests%20To%20Detect%20Mycobacterium%20tuberculosis%20and%20Related%20Drug%20Resistance&rft.jtitle=Journal%20of%20clinical%20microbiology&rft.au=Tessema,%20Belay&rft.date=2017-04-01&rft.volume=55&rft.issue=4&rft.spage=1066&rft.epage=1073&rft.pages=1066-1073&rft.issn=0095-1137&rft.eissn=1098-660X&rft_id=info:doi/10.1128/JCM.01662-16&rft_dat=%3Cproquest_pubme%3E1861575359%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1861575359&rft_id=info:pmid/28100602&rfr_iscdi=true